The value of preoperative imaging in small bowel neuroendocrine tumors

Annals of Surgical Oncology

Volumn 20, Issue 6, 2013, Pages 1912-1917

  Dahdaleh, Fadi S ^a   Lorenzen, Allison ^a   Rajput, Maheen ^a   Carr, Jennifer C ^a   Liao, Junlin ^a   Menda, Yusuf ^a   O'Dorisio, Thomas M ^a   Howe, James R ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN RECEPTOR;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTESTINE RADIOGRAPHY; INTRAOPERATIVE PERIOD; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIMARY TUMOR; RETROSPECTIVE STUDY; SCINTIGRAPHY; SMALL BOWEL NEUROENDOCRINE TUMOR; SMALL INTESTINE TUMOR;

AGED; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PENTETIC ACID; PREOPERATIVE CARE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84878220188     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2836-y     Document Type: Article

References (25)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-59.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
3. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-51.
4. Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O'Dorisio TM, et al. Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution. Ann Surg Oncol. 2012;19:966-972.
5. Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26:991-7.
6. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140:891-7.
7. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39:753-66.
8. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997;41:63-70.
9. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-31.
10. Horton KM, Kamel I, Hofmann L, Fishman EK. Carcinoid tumors of the small bowel: a multitechnique imaging approach. Am J Roentgenol. 2004;182:559-67.
11. Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol. 1907;1:426-32.
12. Scholte A. Ein fall von angioma telangiectaticum cutis mit chronischer endocarditis und malignem dünndarmcarcinoid. Beitr Pathol Anat. 1931;86:440-3.
13. Page IH. Serotonin (5-hydroxytryptamine). Physiol Rev. 1954;34:563-88.
14. Haverback BJ, Sjoerdsma A, Terry LL. Urinary excretion of the serotonin metabolite, 5-hydroxyindoleacetic acid, in various clinical conditions. N Engl J Med. 1956;255:270-2.
15. Hounsfield GN. Computerized transverse axial scanning (tomography). 1. Description of system. Br J Radiol. 1973;46:1016-22.
16. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endoc Relat Cancer. 2010;17:R53-73.
17. Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified. Br J Haematol. 2001;112:936-44.
18. Raderer M, Kurtaran A, Leimer M, Angelberger P, Niederle B, Vierhapper H, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University experience, 1993 to 1998. J Clin Oncol. 2000;18:1331-6.
19. 111In] DTPA-octreotide scintigraphy (octreoscan): a comparative study with CT and MR imaging. Q J Math. 1998;91:295-301.
20. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors. J Am Coll Surg. 2010;211:620-7.
21. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocr Metab. 2005;90:3392-400.
22. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-7.
23. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42-8.
24. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-18.
25. Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol. 2011;197:1221-8.